TSE:CRON

Cronos Group Competitors

C$11.11
+0.07 (+0.63 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
C$10.85
Now: C$11.11
C$11.40
50-Day Range
C$11.00
MA: C$12.70
C$15.48
52-Week Range
C$6.54
Now: C$11.11
C$20.08
Volume391,651 shs
Average Volume1.05 million shs
Market CapitalizationC$4.00 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Cronos Group (TSE:CRON) Vs. TRIL, CXR, APS, BU, TH, and BLU

Should you be buying CRON stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Cronos Group, including Trillium Therapeutics (TRIL), Concordia International (CXR), Aptose Biosciences (APS), Burcon NutraScience (BU), Theratechnologies (TH), and BELLUS Health (BLU).

Trillium Therapeutics (TSE:TRIL) and Cronos Group (TSE:CRON) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.

Profitability

This table compares Trillium Therapeutics and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Trillium TherapeuticsN/AN/AN/A
Cronos GroupN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Trillium Therapeutics and Cronos Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Trillium Therapeutics0000N/A
Cronos Group01202.67

Trillium Therapeutics currently has a consensus price target of C$25.00, suggesting a potential upside of 91.42%. Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Trillium Therapeutics' higher possible upside, research analysts plainly believe Trillium Therapeutics is more favorable than Cronos Group.

Valuation & Earnings

This table compares Trillium Therapeutics and Cronos Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trillium TherapeuticsC$148,000.008,886.89C$-88,724,629.00C($0.88)-14.82
Cronos GroupC$46.72 million85.67C$-76,374,908.00C($0.21)-52.41

Cronos Group has higher revenue and earnings than Trillium Therapeutics. Cronos Group is trading at a lower price-to-earnings ratio than Trillium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Trillium Therapeutics on 4 of the 7 factors compared between the two stocks.

Concordia International (TSE:CXR) and Cronos Group (TSE:CRON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Concordia International and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Concordia InternationalN/AN/AN/A
Cronos GroupN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Concordia International and Cronos Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Concordia International0000N/A
Cronos Group01202.67

Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%.

Earnings and Valuation

This table compares Concordia International and Cronos Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Concordia InternationalC$569.62 million0.00C$17.20 billionC$351.68N/A
Cronos GroupC$46.72 million85.67C$-76,374,908.00C($0.21)-52.41

Concordia International has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Concordia International, indicating that it is currently the more affordable of the two stocks.

Summary

Concordia International beats Cronos Group on 4 of the 5 factors compared between the two stocks.

Aptose Biosciences (TSE:APS) and Cronos Group (TSE:CRON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Aptose Biosciences and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/AN/AN/A
Cronos GroupN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Aptose Biosciences and Cronos Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00203.00
Cronos Group01202.67

Aptose Biosciences currently has a consensus price target of C$12.00, suggesting a potential upside of 81.54%. Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Aptose Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Aptose Biosciences is more favorable than Cronos Group.

Earnings and Valuation

This table compares Aptose Biosciences and Cronos Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/AN/AC($0.68)-9.79
Cronos GroupC$46.72 million85.67C$-76,374,908.00C($0.21)-52.41

Aptose Biosciences has higher earnings, but lower revenue than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Aptose Biosciences beats Cronos Group on 3 of the 5 factors compared between the two stocks.

Burcon NutraScience (TSE:BU) and Cronos Group (TSE:CRON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Burcon NutraScience and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burcon NutraScienceN/AN/AN/A
Cronos GroupN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Burcon NutraScience and Cronos Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burcon NutraScience00103.00
Cronos Group01202.67

Burcon NutraScience currently has a consensus price target of C$5.00, suggesting a potential downside of 7.75%. Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Burcon NutraScience's stronger consensus rating and higher possible upside, equities analysts plainly believe Burcon NutraScience is more favorable than Cronos Group.

Earnings and Valuation

This table compares Burcon NutraScience and Cronos Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burcon NutraScienceC$12,045.0048,193.23C$107,101.00C$0.005,420.00
Cronos GroupC$46.72 million85.67C$-76,374,908.00C($0.21)-52.41

Burcon NutraScience has higher earnings, but lower revenue than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Burcon NutraScience, indicating that it is currently the more affordable of the two stocks.

Summary

Burcon NutraScience beats Cronos Group on 6 of the 8 factors compared between the two stocks.

Theratechnologies (TSE:TH) and Cronos Group (TSE:CRON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Theratechnologies and Cronos Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TheratechnologiesN/AN/AN/A
Cronos GroupN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent recommendations for Theratechnologies and Cronos Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Theratechnologies02002.00
Cronos Group01202.67

Theratechnologies currently has a consensus price target of C$3.75, suggesting a potential downside of 21.38%. Cronos Group has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Cronos Group's stronger consensus rating and higher possible upside, analysts plainly believe Cronos Group is more favorable than Theratechnologies.

Earnings and Valuation

This table compares Theratechnologies and Cronos Group's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TheratechnologiesC$66.05 million6.78C$-27,589,254.00C($0.29)-16.22
Cronos GroupC$46.72 million85.67C$-76,374,908.00C($0.21)-52.41

Theratechnologies has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

Cronos Group beats Theratechnologies on 5 of the 8 factors compared between the two stocks.

Cronos Group (TSE:CRON) and BELLUS Health (TSE:BLU) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Earnings & Valuation

This table compares Cronos Group and BELLUS Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupC$46.72 million85.67C$-76,374,908.00C($0.21)-52.41
BELLUS HealthC$15,000.0028,462.44C$-42,145,306.00C($0.54)-10.13

BELLUS Health has lower revenue, but higher earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than BELLUS Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings for Cronos Group and BELLUS Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group01202.67
BELLUS Health01202.67

Cronos Group presently has a consensus price target of C$9.68, suggesting a potential downside of 12.87%. Given Cronos Group's higher possible upside, research analysts clearly believe Cronos Group is more favorable than BELLUS Health.

Profitability

This table compares Cronos Group and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos GroupN/AN/AN/A
BELLUS HealthN/AN/AN/A


Cronos Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
TRIL
Trillium Therapeutics
0.9$13.06+7.6%C$1.32 billionC$148,000.00-14.82News Coverage
Gap Down
Concordia International logo
CXR
Concordia International
0.7N/AN/AC$1.22 billionC$569.62 million0.07High Trading Volume
APS
Aptose Biosciences
1.3$6.61+1.7%C$587.53 millionN/A-9.79
BU
Burcon NutraScience
1.2$5.42+0.9%C$580.49 millionC$12,045.005,420.00News Coverage
Theratechnologies logo
TH
Theratechnologies
0.7$4.77+0.8%C$447.62 millionC$66.05 million-16.22Upcoming Earnings
News Coverage
BLU
BELLUS Health
0.5$5.45+1.5%C$426.94 millionC$15,000.00-10.13Gap Up
NRI
Nuvo Pharmaceuticals Inc. (NRI.TO)
0.8$35.95+0.6%C$409.34 millionC$76.09 million-58.64News Coverage
ProMetic Life Sciences logo
PLI
ProMetic Life Sciences
0.5N/AN/AC$315.66 millionC$39.91 million-0.22News Coverage
NEPT
Neptune Wellness Solutions
1.2$1.77+4.0%C$292.92 millionC$52.78 million-1.31Gap Up
MDNA
Medicenna Therapeutics
0.5$5.08+0.8%C$268.74 millionN/A-16.44
ONC
Oncolytics Biotech
1.0$4.99+16.2%C$259.90 millionN/A-8.91News Coverage
Gap Down
EMC
Emblem
0.5$1.88+1.6%$248.31 million$5.71 million-9.89
IMV logo
IMV
IMV
1.2$3.62+0.6%C$245.11 millionC$3,000.00-6.26
ATE
Antibe Therapeutics
1.3$4.88+1.0%C$222.07 millionC$9.33 million-6.20Gap Down
FRX
Fennec Pharmaceuticals
0.5$7.82+6.5%C$203.34 millionC$170,000.00-10.24
RVX
Resverlogix
0.7$0.86+0.0%C$202.07 millionN/A78.18Upcoming Earnings
HBP
Helix BioPharma
0.5$0.92+1.1%C$129.84 millionN/A-16.73
IPA
ImmunoPrecise Antibodies
0.4$15.41+4.9%C$123.03 millionC$17.18 million-72.01News Coverage
Gap Up
ACST
Acasti Pharma Inc. (ACST.V)
0.7$0.68+1.5%C$88.79 millionC$81,000.0025.19Gap Down
NVH
Novoheart
0.5$0.53+1.9%C$79.23 millionC$423,500.00-13.95
PMN
ProMIS Neurosciences
0.5$0.22+0.0%C$67.31 millionC$1,787.00-11.00
PDP
Pediapharm
0.5$0.30+1.7%C$66.36 millionC$11.16 million-4.11
MBX
Microbix Biosystems
0.9$0.55+3.6%C$60.20 millionC$11.64 million-10.78News Coverage
Gap Up
SBM
Sirona Biochem
0.5$0.38+1.3%C$58.80 millionC$123,870.00-29.23
COV
Covalon Technologies
0.6$1.41+9.2%C$37.44 millionC$23.84 million-5.92News Coverage
Gap Up
Emerald Health Therapeutics logo
EMH
Emerald Health Therapeutics
0.5$0.29+1.7%C$34.02 millionC$13.02 million-0.42
IGX
IntelGenx Technologies
0.9$0.57+3.5%C$30.87 millionC$1.54 million-8.77News Coverage
QPT
Quest PharmaTech
0.8$0.11+9.1%C$21.76 millionC$38,871.000.17High Trading Volume
CZO
Ceapro
0.7$0.72+4.2%C$21.65 millionC$16.14 million21.82News Coverage
CTX
Crescita Therapeutics
0.6$0.86+2.3%C$17.76 millionC$15.64 million430.00
KNE
Kane Biotech
0.4$0.17+0.0%C$14.12 millionC$1.34 million-4.86
GSD
Devonian Health Group
0.5$0.27+3.7%C$13.96 millionC$1.59 million-5.63Gap Up
PAS
Pascal Biosciences
0.6$0.09+5.6%C$12.70 millionN/A-4.09
NSP
Naturally Splendid Enterprises
0.6$0.06+0.0%C$11.06 millionC$2.03 million-1.40Gap Down
MPH
Medicure
0.7$1.60+5.0%C$10.80 millionC$12.71 million-1.03Gap Down
BTI
Bioasis Technologies
0.7$0.39+3.8%C$10.16 millionC$4.12 million35.45
HEM
Hemostemix
0.6$0.49+1.0%C$9.07 millionN/A-2.92News Coverage
Gap Down
ICO
iCo Therapeutics
0.5$0.11+0.0%C$7.69 millionN/A-8.75
IBT
IBEX Technologies
0.7$0.36+1.4%C$6.94 millionC$5.60 million6.57Gap Down
IOT
Innovotech
0.8$0.15+13.3%C$6.52 millionC$1.04 million75.00Gap Up
BCT
BriaCell Therapeutics
0.5$6.40+15.3%C$4.48 millionN/A-2.07High Trading Volume
Gap Down
RVV
Revive Therapeutics
0.5$0.08+12.5%C$3.62 millionN/A-3.64High Trading Volume
News Coverage
Gap Down
COT
Cotinga Pharmaceuticals Inc. (COT.V)
0.5$0.04+71.4%C$1.54 millionN/A-0.30Upcoming Earnings
Gap Up
PBS
Pacgen Life Science Co. (PBS.V)
0.6$0.03+16.7%C$1.30 millionC$302,079.00-5.00Gap Down
MFS
Medifocus Inc. (MFS.V)
0.5$0.01+0.0%C$925,000.00C$2.23 million-1.00
CHV
(CHV)
0.5N/AN/A$0.00N/A0.00High Trading Volume
PREV
(PREV)
0.7N/AN/A$0.00N/A0.00High Trading Volume
COM
138267 (COM.TO)
0.5N/AN/AC$0.00N/A0.00
MYM
17031
0.4N/AN/AC$0.00N/A0.00
CURE
Direxion Daily Healthcare Bull 3X Shares
0.5N/AN/A$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.